Tocilizumab injection cycle: how often is appropriate

Tocilizumab is a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor. It is suitable for the treatment of a variety of autoimmune diseases, including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (PJIA), systemic juvenile idiopathic arthritis (SJIA), systemic sclerosis-related interstitial lung disease (SSc-ILD), cytokine release syndrome (CRS), and severe coronavirus pneumonia (COVID-19).

The frequency of dosing of tocilizumab will vary based on the treatment indication, patient weight, severity of illness, and the method of administration used. For adult patients with rheumatoid arthritis, intravenous infusion of 4 mg/kg once every 4 weeks is usually recommended, which can be adjusted to 8 mg/kg based on treatment response. In the subcutaneous injection regimen, the dose is generally 162 mg once a week. Patients with giant cell arteritis mostly use subcutaneous injection, 162 mg per week, or intravenous infusion once every 4 weeks.

For juvenile idiopathic arthritis, the frequency of intravenous injection for children with different weights and conditions ranges from once every 2 to 4 weeks. For cytokine release syndrome caused by CAR-T cell therapy, tocilizumab can be administered as a single or multiple emergency intravenous injections with intervals of more than 8 hours based on acute inflammation. Among patients with severe COVID-19 pneumonia, a one-time injection of 8 mg/kg may also be considered. If the effect is not good, an additional dose may be given after 8 hours.

Therefore, there is no unified standard injection cycle for tocilizumab, but it needs to be flexibly formulated according to specific diseases and individual conditions. Usually intravenous injection is once every 2 to 4 weeks, and subcutaneous injection is mostly once a week. Reasonable arrangements need to be made under the guidance of a doctor. Correct injection intervals not only help control disease activity but also avoid the risk of infection and liver damage associated with drug overuse. For patients on long-term treatment, blood and liver and kidney functions should be monitored regularly to ensure safety and efficacy.

Reference materials:https://www.drugs.com/mtm/tocilizumab.html